Company news

Cartesian Therapeutics, Inc. news in 2025

Cartesian Therapeutics, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Cartesian Therapeutics Announces the Appointment of Adrian Bot to Board of Directors

December 18, 2025

Cartesian Therapeutics Announces Strong Efficacy Signal in Phase 2 Trial of Descartes-08 in Patients with SLE and Expansion of Clinical Development into Myositis

November 13, 2025

Cartesian Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 6, 2025

Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors

October 30, 2025

Cartesian Therapeutics Announces New Employment Inducement Grant

October 3, 2025

Cartesian Therapeutics to Participate in Upcoming Investor Conferences

August 28, 2025

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025

Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial

April 8, 2025

Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference

April 1, 2025

Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update

March 13, 2025

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis

January 26, 2025

Decks in 2025